NORDIC NANOVECTOR ASA [Cboe]
NORDIC NANOVECTOR ASA [Cboe]
35.38 NOK (+4.30%)
15 min delay - ChiX CH/DK/FI/NO/SE
Open: 33.70
Change: +1.46
Volume: 2,739
Low: 33.50
High: 35.38
High / Low range: 1.88
Type: Stocks
Ticker: NANO_NO
ISIN: NO0010597883

Nordic Nanovector ASA: Invitation to First Quarter 2019 Results Presentation and Webcast

  • 15
Nordic Nanovector ASA: Invitation to First Quarter 2019 Results Presentation and Webcast

PR Newswire

OSLO, Norway, May 16, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its first quarter 2019 results on Thursday, 23 May 2019.

A presentation by Nordic Nanovector's senior management team will take place at 8:30am CEST at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: NYLAND 

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CEST the same day.

For further information, please contact: 

IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com 

Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com  

About Nordic Nanovector: 

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need,

representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-first-quarter-2019-results-presentation-and-webcast,c2815121

PR Newswire